At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Osilodrostatdrug
Likely dose
Osilodrostat 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease
In Brief
A Phase 2 clinical trial evaluating Osilodrostat for Cushing's Syndrome and 5 related conditions. Completed, enrolled 9 participants across 4 sites.
Detailed Summary
The study aim was to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCushing's Syndrome, Ectopic Corticotropin Syndrome, Adrenal Adenoma, Adrenal Carcinoma, AIMAH, PPNAD
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartSep 2015
Primary CompletionJun 2018
Study CompletionOct 2018
TodayJul 2026
First PostedJun 10, 2015
Enrollment StartSep 24, 2015
Primary CompletionJun 7, 2018
Study CompletionOct 29, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.1 years ago
Interventions
Osilodrostatdrug
Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.